6-Chloro-MDA

6-Chloro-MDA, also known as 6-chloro-3,4-methylenedioxyamphetamine or as 2-chloro-4,5-methylenedioxyamphetamine, is a psychoactive drug of the phenethylamine, amphetamine, and MDxx families related to 3,4-methylenedioxyamphetamine. It is the 6-chloro derivative of MDA. The drug has an active dose of 160mg orally and a duration of approximately 8hours. It is a weak monoamine oxidase inhibitor. 6-Chloro-MDA was first described in the scientific literature by 1970. The properties of 6-chloro-MDA in humans were described by Daniel Trachsel and colleagues in 2013 via personal communication with P. Rausch in 2009.